{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:14:36Z","timestamp":1787786076617,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2021R1A2C2011361"],"award-info":[{"award-number":["2021R1A2C2011361"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12282-025-01818-z","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:25:30Z","timestamp":1769844330000},"page":"377-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4482-3098","authenticated-orcid":false,"given":"Min-Seung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1782-2262","authenticated-orcid":false,"given":"Youngjin","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-1537","authenticated-orcid":false,"given":"Jee Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7832-7116","authenticated-orcid":false,"given":"Eun Hye","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9328-9389","authenticated-orcid":false,"given":"In-Gu","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1154-3137","authenticated-orcid":false,"given":"Hee-Yeon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-4205","authenticated-orcid":false,"given":"Hyosoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-6519","authenticated-orcid":false,"given":"Eun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-0700","authenticated-orcid":false,"given":"Min-Jung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"1818_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"key":"1818_CR2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant Chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485\u2013505.","journal-title":"J Clin Oncol"},{"key":"1818_CR3","doi-asserted-by":"crossref","unstructured":"Qiu W, Dincer AB, Janizek JD, Celik S, Pittet M, Naxerova K et al. Deep profiling of gene expression across 18 human cancers. Nat Biomed Eng. 2025;9:333\u2013355.","DOI":"10.1038\/s41551-024-01290-8"},{"key":"1818_CR4","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1111\/j.1582-4934.2009.00906.x","volume":"13","author":"FC Geyer","year":"2009","unstructured":"Geyer FC, Lopez-Garcia MA, Lambros MB, Reis-Filho JS. Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med. 2009;13:4090\u2013103.","journal-title":"J Cell Mol Med"},{"key":"1818_CR5","doi-asserted-by":"publisher","first-page":"103997","DOI":"10.1016\/j.esmoop.2024.103997","volume":"9","author":"K Fanucci","year":"2024","unstructured":"Fanucci K, Giordano A, Erick T, Tolaney SM, Sammons S. Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT)\/mammalian target of Rapamycin (mTOR) pathway in hormone receptor-positive\/human epidermal growth factor receptor 2 (HER2)-negative (HR+\/HER2-) advanced breast cancer. ESMO Open. 2024;9:103997.","journal-title":"ESMO Open"},{"key":"1818_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M. Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther. 2024;31:1283\u201391.","journal-title":"Cancer Gene Ther"},{"key":"1818_CR7","doi-asserted-by":"publisher","first-page":"1385577","DOI":"10.3389\/fonc.2024.1385577","volume":"14","author":"B Sharaf","year":"2024","unstructured":"Sharaf B, Hajahjeh A, Bani Hani H, Abdel-Razeq H. Next generation selective Estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer. Front Oncol. 2024;14:1385577.","journal-title":"Front Oncol"},{"key":"1818_CR8","doi-asserted-by":"publisher","first-page":"100917","DOI":"10.1016\/j.gim.2023.100917","volume":"25","author":"PJ Ho","year":"2023","unstructured":"Ho PJ, Lim EH, Hartman M, Wong FY, Li J. Breast cancer risk stratification using genetic and non-genetic risk assessment tools for 246,142 women in the UK biobank. Genet Med. 2023;25:100917.","journal-title":"Genet Med"},{"key":"1818_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3348\/kjr.2018.0231","volume":"20","author":"J Koh","year":"2019","unstructured":"Koh J, Kim MJ. Introduction of a new staging system of breast cancer for radiologists: an emphasis on the prognostic stage. Korean J Radiol. 2019;20:69\u201382.","journal-title":"Korean J Radiol"},{"key":"1818_CR10","doi-asserted-by":"crossref","unstructured":"Ji JH, Ahn SG, Yoo Y, Park SY, Kim JH, Jeong JY et al. Prediction of a Multi-Gene assay (Oncotype DX and Mammaprint) recurrence risk group using machine learning in Estrogen Receptor-Positive, HER2-Negative breast Cancer-The BRAIN study. Cancers (Basel). 2024;16:774.","DOI":"10.3390\/cancers16040774"},{"key":"1818_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s12282-025-01673-y","volume":"32","author":"MS Park","year":"2025","unstructured":"Park MS, Cho EH, Youn Y, Do IG, Woo HY, Park H, et al. Importance of Circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients. Breast Cancer. 2025;32:416\u201325.","journal-title":"Breast Cancer"},{"key":"1818_CR12","first-page":"63","volume":"4","author":"N Guo","year":"2024","unstructured":"Guo N, Zhou Q, Chen X, Zeng B, Wu S, Zeng H, et al. Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis. J Natl Cancer Cent. 2024;4:63\u201373.","journal-title":"J Natl Cancer Cent"},{"key":"1818_CR13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.annonc.2023.09.3111","volume":"34","author":"E Agostinetto","year":"2023","unstructured":"Agostinetto E, Ignatiadis M. CtDNA as a predictive biomarker in advanced breast cancer: lessons from the MONALEESA studies. Ann Oncol. 2023;34:955\u20139.","journal-title":"Ann Oncol"},{"key":"1818_CR14","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/s41467-025-57988-z","volume":"16","author":"S Li","year":"2025","unstructured":"Li S, Li Y, Wei W, Gong C, Wang T, Li G, et al. Dynamic ctdna tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy. Nat Commun. 2025;16:2786.","journal-title":"Nat Commun"},{"key":"1818_CR15","doi-asserted-by":"crossref","unstructured":"Winn JS, Hasse Z, Slifker M, Pei J, Arisi-Fernandez SM, Talarchek JN et al. Genetic variants detected using Cell-Free DNA from blood and tumor samples in patients with inflammatory breast cancer. Int J Mol Sci. 2020; 21:1290.","DOI":"10.3390\/ijms21041290"},{"key":"1818_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00018-019-03189-z","volume":"77","author":"C Keup","year":"2020","unstructured":"Keup C, Benyaa K, Hauch S, Sprenger-Haussels M, Tewes M, Mach P, et al. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. Cell Mol Life Sci. 2020;77:497\u2013509.","journal-title":"Cell Mol Life Sci"},{"key":"1818_CR17","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1038\/s41467-018-05914-x","volume":"9","author":"OL Griffith","year":"2018","unstructured":"Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, et al. The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018;9:3476.","journal-title":"Nat Commun"},{"key":"1818_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-019-05512-5","volume":"180","author":"T Shibayama","year":"2020","unstructured":"Shibayama T, Low SK, Ono M, Kobayashi T, Kobayashi K, Fukada I, et al. Clinical significance of gene mutation in ctdna analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;180:331\u201341.","journal-title":"Breast Cancer Res Treat"},{"key":"1818_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/0008-5472.CAN-23-1429","volume":"84","author":"J Heo","year":"2024","unstructured":"Heo J, Kim YN, Shin S, Lee K, Lee JH, Lee YJ, et al. Serial Circulating tumor DNA analysis with a tumor-Naive Next-Generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer. Cancer Res. 2024;84:468\u201378.","journal-title":"Cancer Res"},{"key":"1818_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular Pathology, American society of clinical Oncology, and college of American pathologists. J Mol Diagn. 2017;19:4\u201323.","journal-title":"J Mol Diagn"},{"key":"1818_CR21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.21037\/gs-24-115","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Feng R, Xu Y, Yang L, Xie F, Yang H, et al. Baseline Circulating tumor DNA predicts long-term survival outcomes for patients with early breast cancer. Gland Surg. 2024;13:684\u201396.","journal-title":"Gland Surg"},{"key":"1818_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13058-018-1044-5","volume":"20","author":"NA Ungerleider","year":"2018","unstructured":"Ungerleider NA, Rao SG, Shahbandi A, Yee D, Niu T, Frey WD, et al. Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Res. 2018;20:115.","journal-title":"Breast Cancer Res"},{"key":"1818_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/cac2.12032","volume":"40","author":"Z Yi","year":"2020","unstructured":"Yi Z, Ma F, Rong G, Guan Y, Li C, Xu B. Clinical spectrum and prognostic value of TP53 mutations in Circulating tumor DNA from breast cancer patients in China. Cancer Commun (Lond). 2020;40:260\u20139.","journal-title":"Cancer Commun (Lond)"},{"key":"1818_CR24","doi-asserted-by":"crossref","unstructured":"Arimura A, Sakai K, Kaneshiro K, Morisaki T, Hayashi S, Mizoguchi K et al. TP53 and\/or BRCA1 mutations based on ctdna analysis as prognostic biomarkers for primary Triple-Negative breast cancer. Cancers (Basel). 2024;16:1184.","DOI":"10.3390\/cancers16061184"},{"key":"1818_CR25","doi-asserted-by":"publisher","first-page":"e2200148","DOI":"10.1200\/PO.22.00148","volume":"6","author":"F Cailleux","year":"2022","unstructured":"Cailleux F, Agostinetto E, Lambertini M, Rothe F, Wu HT, Balcioglu M, et al. Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse. JCO Precis Oncol. 2022;6:e2200148.","journal-title":"JCO Precis Oncol"},{"key":"1818_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32:229\u201339.","journal-title":"Ann Oncol"},{"key":"1818_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.21037\/tlcr.2020.03.17","volume":"9","author":"Y Song","year":"2020","unstructured":"Song Y, Hu C, Xie Z, Wu L, Zhu Z, Rao C, et al. Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Transl Lung Cancer Res. 2020;9:269\u201379.","journal-title":"Transl Lung Cancer Res"},{"key":"1818_CR28","doi-asserted-by":"crossref","unstructured":"Niemann B, Moise J, Sestito M, Malla M, Train K, Murken D et al. Circulating tumor DNA (ctDNA) clearance May predict treatment response in neoadjuvant colorectal cancer management. J Clin Med. 2024;13:1684.","DOI":"10.3390\/jcm13061684"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01818-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01818-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01818-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:57:18Z","timestamp":1772621838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01818-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1818"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01818-z","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Kangbuk Samsung Hospital (IRB No. 2018-06-054), and informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval & Patient consent"}}]}}